These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 24002405)
1. Dyslipidemia and oxidative stress in PCOS. Macut D; Bjekić-Macut J; Savić-Radojević A Front Horm Res; 2013; 40():51-63. PubMed ID: 24002405 [TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS. Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204 [TBL] [Abstract][Full Text] [Related]
3. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589 [TBL] [Abstract][Full Text] [Related]
4. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Bayram F; Kocer D; Ozsan M; Muhtaroglu S Gynecol Endocrinol; 2012 Jul; 28(7):497-501. PubMed ID: 22703625 [TBL] [Abstract][Full Text] [Related]
6. Hypoadiponectinemia: a useful marker of dyslipidemia in women with polycystic ovary syndrome. Chang CY; Chen MJ; Yang WS; Yeh CY; Ho HN; Chen SU; Yang YS Taiwan J Obstet Gynecol; 2012 Dec; 51(4):583-90. PubMed ID: 23276562 [TBL] [Abstract][Full Text] [Related]
7. Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome. Hernández-Mijares A; Bañuls C; Gómez-Balaguer M; Bergoglio M; Víctor VM; Rocha M Eur J Clin Invest; 2013 Jun; 43(6):549-56. PubMed ID: 23528141 [TBL] [Abstract][Full Text] [Related]
8. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993 [TBL] [Abstract][Full Text] [Related]
9. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Kim JJ; Chae SJ; Choi YM; Hwang KR; Song SH; Yoon SH; Kim SM; Ku SY; Kim SH; Kim JG; Moon SY Hum Reprod; 2013 May; 28(5):1354-60. PubMed ID: 23477907 [TBL] [Abstract][Full Text] [Related]
10. Pathophysiology and types of dyslipidemia in PCOS. Diamanti-Kandarakis E; Papavassiliou AG; Kandarakis SA; Chrousos GP Trends Endocrinol Metab; 2007 Sep; 18(7):280-5. PubMed ID: 17692530 [TBL] [Abstract][Full Text] [Related]
11. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Rizzo M; Berneis K; Carmina E; Rini GB Am J Obstet Gynecol; 2008 Jan; 198(1):28.e1-5. PubMed ID: 18166299 [TBL] [Abstract][Full Text] [Related]
12. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Kocer D; Bayram F; Diri H Gynecol Endocrinol; 2014 May; 30(5):367-71. PubMed ID: 24517721 [TBL] [Abstract][Full Text] [Related]
13. Lipid and lipoprotein profile in women with polycystic ovary syndrome. Macut D; Panidis D; Glisić B; Spanos N; Petakov M; Bjekić J; Stanojlović O; Rousso D; Kourtis A; Bozić I; Damjanović S Can J Physiol Pharmacol; 2008 Apr; 86(4):199-204. PubMed ID: 18418429 [TBL] [Abstract][Full Text] [Related]
14. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. Rocha MP; Marcondes JA; Barcellos CR; Hayashida SA; Curi DD; da Fonseca ÂM; Bagnoli VR; Baracat EC Gynecol Endocrinol; 2011 Oct; 27(10):814-9. PubMed ID: 20807166 [TBL] [Abstract][Full Text] [Related]
15. Detailed characterisation of circulatory nitric oxide and free radical indices--is there evidence for abnormal cardiovascular homeostasis in young women with polycystic ovary syndrome? Willis GR; Udiawar M; Evans WD; Blundell HL; James PE; Rees DA BJOG; 2014 Dec; 121(13):1596-603. PubMed ID: 24816317 [TBL] [Abstract][Full Text] [Related]
16. Antioxidant properties of high-density lipoproteins are impaired in women with polycystic ovary syndrome. Zhang J; Zhang Y; Liu H; Bai H; Wang Y; Jiang C; Fan P Fertil Steril; 2015 May; 103(5):1346-54. PubMed ID: 25813288 [TBL] [Abstract][Full Text] [Related]
17. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. Hyderali BN; Mala K Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():15-22. PubMed ID: 26066290 [TBL] [Abstract][Full Text] [Related]
18. Changes in the PCOS phenotype with age. Hsu MI Steroids; 2013 Aug; 78(8):761-6. PubMed ID: 23624031 [TBL] [Abstract][Full Text] [Related]
19. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Demirel F; Bideci A; Cinaz P; Camurdan MO; Biberoğlu G; Yesilkaya E; Hasanoğlu A Clin Endocrinol (Oxf); 2007 Jul; 67(1):129-34. PubMed ID: 17465999 [TBL] [Abstract][Full Text] [Related]
20. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Diamanti-Kandarakis E; Kandaraki E; Christakou C; Panidis D Obes Rev; 2009 Jul; 10(4):431-41. PubMed ID: 19413702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]